Literature DB >> 22670112

Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study.

D Rayson1, S Lutes, M Sellon, B Colwell, M Dorreen, A Drucker, A Jeyakumar, S Snow, T Younis.   

Abstract

Entities:  

Year:  2012        PMID： 22670112      PMCID： PMC3364783          DOI： 10.3747/co.19.940

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  8 in total

1.  Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

Authors:  Henri Roché; Pierre Fumoleau; Marc Spielmann; Jean-Luc Canon; Thierry Delozier; Daniel Serin; Michel Symann; Pierre Kerbrat; Patrick Soulié; Françoise Eichler; Patrice Viens; Alain Monnier; Anita Vindevoghel; Mario Campone; Marie-Josèphe Goudier; Jacques Bonneterre; Jean-Marc Ferrero; Anne-Laure Martin; Jean Genève; Bernard Asselain
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

3.  Hematopoietic growth factors: ESMO recommendations for the application.

Authors:  R Greil; O Psenak
Journal:  Ann Oncol       Date:  2007-04       Impact factor: 32.976

4.  High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide.

Authors:  Derrick Soong; Reem Haj; Mova G Leung; Robert Myers; Brian Higgins; Jeff Myers; Sudha Rajagopal
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

5.  Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres.

Authors:  Y Madarnas; S F Dent; S F Husain; A Robinson; S Alkhayyat; W M Hopman; J L Verreault; T Vandenberg
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

Review 6.  A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.

Authors:  G H Lyman
Journal:  Eur J Cancer       Date:  2000-04       Impact factor: 9.162

7.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Authors:  Stephen E Jones; Michael A Savin; Frankie Ann Holmes; Joyce A O'Shaughnessy; Joanne L Blum; Svetislava Vukelja; Kristi J McIntyre; John E Pippen; James H Bordelon; Robert Kirby; John Sandbach; William J Hyman; Pankaj Khandelwal; Angel G Negron; Donald A Richards; Stephen P Anthony; Robert G Mennel; Kristi A Boehm; Walter G Meyer; Lina Asmar
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

8.  Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer.

Authors:  Wylie Hosmer; Jennifer Malin; Mitchell Wong
Journal:  Support Care Cancer       Date:  2010-02-24       Impact factor: 3.603
  8 in total
  5 in total

1.  Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.

Authors:  Joy Bacrie; Marc Laurans; Pauline Iorio; Emmanuelle Fourme; Anne Béthune Volters; Laurence Bozec; Florence Lerebours; Coraline Dubot; Okba Bensaoula; Bilel Benzidane; Jean-Yves Pierga; Delphine Lefeuvre
Journal:  Support Care Cancer       Date:  2018-05-31       Impact factor: 3.603

2.  A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.

Authors:  Mova Leung; Joy Florendo; Jessica Kano; Tiffany Marr-Del Monte; Brian Higgins; Robert Myers; Trishala Menon; Glenn Jones
Journal:  Support Care Cancer       Date:  2014-11-26       Impact factor: 3.603

3.  Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.

Authors:  Hazem Assi; Joshua Murray; Laura Boyle; Daniel Rayson
Journal:  Support Care Cancer       Date:  2014-07-05       Impact factor: 3.603

4.  A model of hematopoietic stem cell proliferation under the influence of a chemotherapeutic agent in combination with a hematopoietic inducing agent.

Authors:  Christina L Mouser; Eliana S Antoniou; James Tadros; Evros K Vassiliou
Journal:  Theor Biol Med Model       Date:  2014-01-17       Impact factor: 2.432

5.  Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.

Authors:  Ricardo Fernandes; Sasha Mazzarello; Carol Stober; Mohamed F K Ibrahim; Shaan Dudani; Kirstin Perdrizet; Habeeb Majeed; Lisa Vandermeer; Risa Shorr; Brian Hutton; Dean Fergusson; Bishal Gyawali; Mark Clemons
Journal:  J Glob Oncol       Date:  2017-04-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.